IL217857A - Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone) - Google Patents

Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone)

Info

Publication number
IL217857A
IL217857A IL217857A IL21785712A IL217857A IL 217857 A IL217857 A IL 217857A IL 217857 A IL217857 A IL 217857A IL 21785712 A IL21785712 A IL 21785712A IL 217857 A IL217857 A IL 217857A
Authority
IL
Israel
Prior art keywords
ganaxolone
3alpha
5alpha
pregnan
3beta
Prior art date
Application number
IL217857A
Other languages
English (en)
Hebrew (he)
Other versions
IL217857A0 (en
Original Assignee
Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinus Pharmaceuticals Inc, Marinus Pharmaceuticals filed Critical Marinus Pharmaceuticals Inc
Publication of IL217857A0 publication Critical patent/IL217857A0/en
Publication of IL217857A publication Critical patent/IL217857A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL217857A 2009-08-13 2012-01-31 Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone) IL217857A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23355309P 2009-08-13 2009-08-13
PCT/US2010/045176 WO2011019821A2 (en) 2009-08-13 2010-08-11 METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE)

Publications (2)

Publication Number Publication Date
IL217857A0 IL217857A0 (en) 2012-03-29
IL217857A true IL217857A (en) 2016-03-31

Family

ID=43586809

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217857A IL217857A (en) 2009-08-13 2012-01-31 Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone)

Country Status (14)

Country Link
US (1) US8362286B2 (enExample)
EP (1) EP2464653B1 (enExample)
JP (1) JP5745517B2 (enExample)
KR (1) KR101778603B1 (enExample)
CN (1) CN102549007B (enExample)
AU (1) AU2010282570B2 (enExample)
BR (1) BR112012003085B1 (enExample)
CA (1) CA2769820C (enExample)
EA (1) EA024269B1 (enExample)
ES (1) ES2524724T3 (enExample)
IL (1) IL217857A (enExample)
MX (1) MX2012001728A (enExample)
NZ (1) NZ597940A (enExample)
WO (1) WO2011019821A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US9629853B2 (en) 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
CZ305837B6 (cs) * 2015-02-25 2016-03-30 Vysoká škola chemicko - technologická v Praze (3α,5β,20S)-3-Nitrooxy-pregnan-20-karboxylová kyselina
KR20180082457A (ko) * 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
CN106366149B (zh) * 2016-08-09 2018-01-23 南京臣功制药股份有限公司 一种醋酸甲羟孕酮分散片的有关物质及其分析检测方法
CN106279326A (zh) * 2016-08-09 2017-01-04 南京臣功制药股份有限公司 一种醋酸甲羟孕酮胶囊的有关物质及其分析检测方法
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
IT201800009683A1 (it) * 2018-10-22 2020-04-22 Ind Chimica Srl Processo per la preparazione di 3α-idrossi-5α-pregnan-20-one (brexanolone)
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
AU2020395254B2 (en) 2019-12-06 2026-04-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
IT202000021316A1 (it) * 2020-09-09 2022-03-09 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Gabaaレセプター複合体と相互作用させるための化合物
FR2720747B1 (fr) * 1994-06-02 1996-07-12 Roussel Uclaf Nouveau procédé de préparation d'un stéroïde 16béta-méthyl et nouveaux intermédiaires.
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
WO2006010085A1 (en) * 2004-07-09 2006-01-26 Roxro Pharma, Inc. Use of neurosteroids to treat neuropathic pain
ES2812250T3 (es) * 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas

Also Published As

Publication number Publication date
WO2011019821A3 (en) 2011-06-16
WO2011019821A2 (en) 2011-02-17
US8362286B2 (en) 2013-01-29
US20110040112A1 (en) 2011-02-17
EA201270241A1 (ru) 2013-09-30
EP2464653B1 (en) 2014-10-22
CN102549007B (zh) 2015-03-18
BR112012003085A2 (pt) 2020-12-01
JP5745517B2 (ja) 2015-07-08
JP2013501803A (ja) 2013-01-17
KR20120084715A (ko) 2012-07-30
KR101778603B1 (ko) 2017-09-14
AU2010282570B2 (en) 2014-04-24
EA024269B1 (ru) 2016-09-30
CA2769820C (en) 2017-06-27
AU2010282570A1 (en) 2012-02-23
EP2464653A4 (en) 2013-01-16
MX2012001728A (es) 2012-06-01
IL217857A0 (en) 2012-03-29
CA2769820A1 (en) 2011-02-17
EP2464653A2 (en) 2012-06-20
HK1171761A1 (en) 2013-04-05
NZ597940A (en) 2013-03-28
ES2524724T3 (es) 2014-12-11
CN102549007A (zh) 2012-07-04
BR112012003085B1 (pt) 2021-06-01

Similar Documents

Publication Publication Date Title
GB0905140D0 (en) Method
GB0911905D0 (en) Method
GB0902476D0 (en) Method
GB0910707D0 (en) Method
IL217857A0 (en) Method for making 3??-hydroxy, 3??- methyl-5??-pregnan-20-one (ganaxolone)
GB0913525D0 (en) Method
GB0921375D0 (en) Method
GB0918940D0 (en) Method
GB0913433D0 (en) Method
GB0901444D0 (en) Method
GB0916570D0 (en) Method
GB0903316D0 (en) Method
ZA201101329B (en) Recarburisation method
GB0917457D0 (en) Method
GB0905367D0 (en) Method
GB0916013D0 (en) Method
GB0908770D0 (en) Method
ZA201203155B (en) Method for isolating methylglycinenitrile-n,n-diacetonitrile
GB0920596D0 (en) Method
GB0902034D0 (en) Method
PL2319671T3 (pl) Sposób wytwarzania płyt OSB
GB0919901D0 (en) Method
GB0917988D0 (en) Method
GB0911362D0 (en) Method
GB0904946D0 (en) Method

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed